News
ASCO 2032: What Will Be the Big Story in Lung Cancer?
New clinical research unveiled at the recent American Society of Clinical Oncology (ASCO) annual meeting has the potential to significantly alter the treatment of lung cancer. But what will be the innovations we are talking about in 5 years? Or 10 years?
In this last of four exclusive episodes, MedPage Today brought together three leaders in the field -- moderator Roy S. Herbst, MD, PhD, of Yale Cancer Center in New Haven, Connecticut, is joined by Jorge Nieva, MD, of the Keck School of Medicine of USC in Los Angeles, and Sarah Goldberg, MD, also of Yale Cancer Center -- for a roundtable discussion on how to get to the next level in lung cancer, and what they and other experts will hopefully be talking about at ASCO over the next decade.
Source: MedPage Today